Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Mr. Ruediger Naumann-Etienne resigned as a member of the Board of Directors
(the “Board”) of Bio-Rad Laboratories, Inc. (the “Company”) effective December 4, 2009. Mr. Naumann-Etienne was an independent director and a member of the Audit and Compensation Committees of the Board. Mr. Naumann-Etienne’s resignation is not related to any disagreement with the Company’s operations, policies or practices.
On December 9, 2009, the Company notified the New York Stock Exchange (“NYSE”) that the Company does not comply with the audit committee composition requirements under Section 303A.07(a) of the NYSE Listed Company Manual as a result of the resignation of Mr. Naumann-Etienne. This resignation left the Company with only two independent directors serving on its Audit Committee rather than the requisite three independent directors. The Company is currently seeking a replacement for Mr. Naumann-Etienne to serve on the Board and the Audit Committee of the Board and intends to regain compliance with the requirements of Section 303A.07(a) of the NYSE Listed Company Manual as soon as practicable.
Market Data 
Markets 
AI
